Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial

Table 7 Adverse events experienced in both groups, n (%)

	Double-stent group (n = 40)	Single-stent group (n = 38)	P value
Adverse events	4 (10.0)	6 (15.8)	0.710
Acute pancreatitis	3 (7.5)	5 (13.2)	-
Acute cholangitis	1 (2.5)	1 (2.6)	-
Hemorrhage	0 (0)	0 (0)	-
Perforation	0 (0)	0 (0)	-

The double-stent group underwent endoscopic retrograde cholangiopancreatography with a fully-covered self-expandable metallic biliary stent and a pancreatic duct stent, while the single-stent group underwent a fully-covered self-expandable metallic biliary stent only.